Iaten

Meloxicam, the active ingredient in Iaten, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral dosage form for oral use. It is used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis and acute musculoskeletal pain. GNH USA supplies Iaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam acts on inflammatory pathways to reduce pain and swelling in several musculoskeletal disorders. - Osteoarthritis: decreases joint pain and improves function. - Rheumatoid arthritis: alleviates chronic inflammation and joint damage progression. - Juvenile rheumatoid arthritis: provides pain relief and reduces disease activity in children. - Ankylosing spondylitis: lessens spinal stiffness and pain. - Acute pain: offers rapid analgesia for short‑term painful episodes.

Adverse reactions may occur with meloxicam therapy.

Common Side Effects: - Gastrointestinal upset (nausea, dyspepsia) - Headache - Dizziness - Mild skin rash

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding - Cardiovascular events such as myocardial infarction - Severe hepatic enzyme elevation - Acute renal impairment - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylactic reactions

Before initiating meloxicam, consider the following safety measures. - Renal function: monitor in patients with existing kidney disease. - Cardiovascular risk: avoid in uncontrolled hypertension or recent coronary events. - Gastrointestinal risk: use cautiously in individuals with a history of ulcers or bleeding. - Pregnancy and lactation: assess risk‑benefit; limited data are available. - Drug interactions: review concomitant NSAIDs, anticoagulants, and other interacting agents. - Store at below 25°C: keep in the original pack, protect from moisture.

Meloxicam may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other selective COX‑2 inhibitors: additive toxicity. - Lithium: elevated serum lithium levels. - Methotrexate: enhanced methotrexate toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible decline in renal function. - Diuretics: heightened risk of renal impairment. - SSRIs or SNRIs: increased potential for gastrointestinal bleeding.